Search Results
Results found for "Marie Sklodowska Curie"
- Radioligands vs. Fluorescent Ligands: Binding Assays
If you are curious about fluorescent probes, fluorescent probe design or GPCR tools, feel free to contact Br J Pharmacol. 2020 Mar;177(5):978-991. doi: 10.1111/bph.14953.
- Your GPCR Program Decisions Depend on Good Data Interpretation
Under certain experimental conditions, what appears to be a second high-affinity site may simply reflect GPCR University Learner Celtarys Research Recap: Medicinal Chemistry Highlights You May Have Missed The technologies overcoming peptide limitations with insights from both pharma and startup environments Read Maria Pin built an in vitro pharmacology group from scratch—not just a lab, but a culture that encouraged curiosity leadership principles: Hire for attitude and team fit—not just credentials Design workflows that enable curiosity-driven
- What If Your Data is Lying to You? The Calcium Assay Dilemma
. 📍 Foundational Level | Calcium Assays 📚 Part of Terry Kenakin’s Pharmacology Vault 👉 Curious what
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientist’s Mission
Takeaway Science isn’t always about curiosity. Sometimes, it’s about necessity. Dr.
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
hired based on attitude and team fit , not just credentials He designed lab workflows that encouraged curiosity
- Pharmacology at Your Fingertips: Terry’s Corner Launches
Stay curious, The Dr. GPCR Team Join Our Newsletter!
- From Ox Liver to AI: How the History of Pharmacology Shapes Its Future
They both mark critical moments in humanity’s centuries-long quest to control physiology—and they bookend Curious yet?
- Signals in Motion: Pain, Metabolism & Terry’s Corner
Maria Majellaro shares her story of innovation and listening-driven science. Maria Majellaro reveals how Celtarys evolved from a vision into a company solving real-world assay problems Read Maria’s Story GPCR Publication Highlights CXCR4 signaling promotes terminal erythropoiesis through Stay curious, stay connected, because the future of GPCR science is being written pathway by pathway.
- Ever Wondered How Drugs Are Discovered?
discovering new drugs, breaking down the science into accessible, engaging insights for early learners and curious
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
Maria Majellaro shares her journey to founding Celtarys in "From Lab to Leadership". Maria Majellaro’s path from lab research to co-founding Celtarys, as told in her recent Dr. Stay curious, The Dr. GPCR Team
- The Chemistry of Confidence: Aha Moments That Shape Scientific Careers
Maria Majellaro’s story, shared in Episode 168 of the Dr. Maria Majellaro Maria didn’t always know she’d end up in a startup. In fact, her early decisions were based on curiosity, instinct, and a surprising love of cooking (yes Maria Majellaro Now, she leads a team of talented chemists at Celtarys, developing fluorescent ligands
- Inside Out: Mapping GPCRs from Membrane Codes to Market Moves
Ilana Kotliar share how three decades of curiosity evolved into a tech-powered platform for mapping GPCR-RAMP
- Science Needs Rigor, But Also Joy
Four hundred plates of assays, concentration-response curves, and mutagenesis screens are standard. Leadership that supports academic career paths • A team that communicates under pressure • Space for curiosity
- Mapping Motion: Intermediate States, Deorphanization & Discovery
GPCR Colleagues & Curiosity-Driven Minds, We’re starting with exciting Dr. Stay curious, The Dr. GPCR Team
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John These compounds may be a novel way to treat pain without the negative side effects of cannabinoids or
- Single-molecule counting applied to the study of GPCR oligomerization
G-protein-coupled receptors-an expansive class of transmembrane signaling proteins that participate in many
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling We hypothesized that somatic mutations in tumor samples may not be enriched within a single gene but rather that cognate mutations with similar effects on GPCR function are distributed across many receptors
- Posttranslational modifications in GPCR internalization
However, many studies over the past decade have reported that internalized membrane receptors can trigger
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
Hey there, curious minds! Want to know what’s buzzing in the world of GPCRs? April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR Annual Meeting 2025 May 12 - 15, 2025 | PEGS 2025 May 20 - 22, 2025 | SLAS Europe 2025 June 16 - 19, 2025 | BIO International
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
the importance of members of the GPCR superfamily as targets of a broad range of effective medicines many Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation
- Location bias contributes to functionally selective responses of biased CXCR3 agonists
Although GPCRs are primarily found at the plasma membrane, GPCRs can traffic to and signal from many
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
Although many cardiovascular GPCRs have been extensively studied as model receptors for decades, new We also discuss how advancing technologies to discover nanobodies with tailored specificities may expand
- Search for safer pain relief advances with new engineered compounds
like morphine and other drugs, provide relief via activation of opioid receptors, but without inducing many
- Dopamine D 1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, behavior...
It is intriguing that many results emerged from behavioral and physiological studies implying that bias
- Chronic itch: emerging treatments following new research concepts
However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
cancer cell cycle and metastasis "β-Arrestins are ubiquitously expressed intracellular proteins with many
- Breaking the Myth of High and Low Affinity Sites
Kenakin challenges this assumption and shows that what you’re seeing may reflect something entirely different In many systems, a ligand may appear to bind with very high affinity when it facilitates formation of
- Computational study of the conformational ensemble of CX3C chemokine receptor 1 (CX3CR1) and its...
GPCR) superfamily, and its ligand fractalkine constitute an important biochemical axis that influence many
- Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
Therefore, mGluR2 and mGluR3 have been considered as potential drug targets for the treatment of many
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
. 👉 Many biotech fundraising efforts stall even with solid science and data. fundraising issue when it is not clearly framed and explained. 3️⃣ No clear Freedom to Operate narrative Many

















